TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25701002

Group type: EXPERIMENTAL
Intervention: 200 mg DHA
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 400 mg DHA
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 24456065

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) HCl
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 22447579

Group type: EXPERIMENTAL
Intervention: GCBT+HA
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: GCBT
Number of subjects: 38

Group type: COMPARATOR
Intervention: BIB
Number of subjects: 38
Study: 19568197

Group type: EXPERIMENTAL
Intervention: L‐arginine hydrochloride capsules (7.2 g x d(‐1))
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 7
Study: 17311785

Group type: EXPERIMENTAL
Intervention: Assistance of digit extension provided by a novel cable orthosis
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Assistance provided by a novel pneumatic orthosis
Number of subjects: 15

Group type: COMPARATOR
Intervention: No assistance provided
Number of subjects: 15
Study: 15607097

Group type: EXPERIMENTAL
Intervention: Fat-suppressed subtraction MRI
Number of subjects: 94
Study: 12070626

Group type: EXPERIMENTAL
Intervention: Moderate exercise training for 12 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 19
Study: 10409565

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g/kg/day for 5 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (trial 1)
Number of subjects: 8
Study: 8567517

Group type: EXPERIMENTAL
Intervention: Precooling test (Pret)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control test (Cont)
Number of subjects: 8
Study: 2155697

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (four cycles) after radiotherapy
Number of subjects: 149

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy (cisplatin-vindesine followed by 6000 cGy of thoracic irradiation)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Initial chemotherapy (vindesine-cisplatin)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Patients with complete response
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Patients with partial or minor response
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Overall treatment (chemotherapy followed by radiotherapy)
Number of subjects: 149
Study: 465407

Group type: EXPERIMENTAL
Intervention: Pilocarpine and phenylephrine
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Iridectomy from the first group
Number of subjects: 76
Study: 31868149

Group type: EXPERIMENTAL
Intervention: Nanocurcumin (40 mg capsule every 12 hours for six weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (similar components of nanomicelle curcumin capsules without curcumin)
Number of subjects: 71
Study: 30918037

Group type: EXPERIMENTAL
Intervention: Pain education intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Guideline-based physiotherapy active control
Number of subjects: 40
Study: 27533333

Group type: EXPERIMENTAL
Intervention: 24% sucrose solution administered orally 2 minutes prior to PIV catheter insertion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo solution administered orally 2 minutes prior to PIV catheter insertion
Number of subjects: 40
Study: 26465927

Group type: EXPERIMENTAL
Intervention: VSL#3 (900 billion live bacteria)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (cornstarch)
Number of subjects: 19
Study: 23111980

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE) 100 mg administered to the mid‐small intestine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE) 100 mg administered to the large intestine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral administration of the IR tablet of RE
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Regional gastrointestinal delivery of RE
Number of subjects: 8
Study: 21871979

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional 4-port laparoscopic cholecystectomy (4-port LC)
Number of subjects: 51
Study: 19840529

Group type: EXPERIMENTAL
Intervention: Exenatide (10 microg b.i.d.)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (b.i.d.)
Number of subjects: 22
Study: 17086074

Group type: EXPERIMENTAL
Intervention: Tinnitus-coping therapy (TCT) with TCI provision
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Tinnitus-coping therapy (TCT) without TCI devices
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waiting-list control group (no treatment for 12 months)
Number of subjects: 70
Study: 15683142

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auto‐titrating Positive Airway Pressure (APAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APAP
Number of subjects: 0
Study: 12392836

Group type: EXPERIMENTAL
Intervention: RVA pacing
Number of subjects: 24

Group type: COMPARATOR
Intervention: RVOT pacing
Number of subjects: 24
Study: 9863541

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg nocte
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8574712

Group type: EXPERIMENTAL
Intervention: Human recombinant EGF administered subcutaneously
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2191753

Group type: EXPERIMENTAL
Intervention: Calcium alginate swabs
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal surgical gauze
Number of subjects: 100
Study: 313873

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) in combination with intramuscularly administered C. parvum
Number of subjects: 33
Study: 31364896

Group type: EXPERIMENTAL
Intervention: Augmented biofeedback training and physical therapy (Group C)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Physical therapy (Group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Augmented biofeedback training (Group B)
Number of subjects: 45
Study: 31969136

Group type: EXPERIMENTAL
Intervention: Family Intervention (FI)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Individual Intervention (II)
Number of subjects: 122
Study: 28958737

Group type: EXPERIMENTAL
Intervention: tDCS (cathodal, 20 min, 1.0 mA, 0.04 mA/cm2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study: 26837463

Group type: EXPERIMENTAL
Intervention: 40-mg oral atomoxetine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 25369014

Group type: EXPERIMENTAL
Intervention: Study guides on thyroid disorders and diabetes
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional training program
Number of subjects: 46
Study: 23469599

Group type: EXPERIMENTAL
Intervention: Yiqi Fumai Injection (YFI) alone, 2.6 g YFI in 250 mL normal saline, once daily for 15 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulfate alone, 0.2 g twice daily for 15 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Yiqi Fumai Injection (YFI) combined with hydroxychloroquine sulfate, same dosages as Groups A and B for 15 days
Number of subjects: 80
Study: 20203451

Group type: EXPERIMENTAL
Intervention: Multiple risk factor intervention strategy based on single‐pill amlodipine besylate/atorvastatin calcium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care strategy
Number of subjects: 0
Study: 18790313

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy-based intervention delivered by trained primary health workers
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control group with untrained health workers making equal visits
Number of subjects: 463
Study: 15863377

Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg per day for 24 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Radiotherapy (one 12-Gy fraction on the day of starting bicalutamide)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Bicalutamide alone (150 mg per day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tamoxifen (in patients who developed gynaecomastia or breast pain)
Number of subjects: 51
Study: 12002672

Group type: EXPERIMENTAL
Intervention: 40 mg Ginkgo biloba extract twice daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: 80 mg Ginkgo biloba extract once daily for 7 days
Number of subjects: 12
Study: 10330737

Group type: EXPERIMENTAL
Intervention: Primer postcard
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (no primer postcard)
Number of subjects: 800
Study: 8983868

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (19 amino acids, 240 kJ/h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (isovolumic infusions of nutrient-free saline solution)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study: 1744992

Group type: EXPERIMENTAL
Intervention: Sulphadimidine 250 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sulphadimidine 500 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sulphadimidine 750 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sulphadimidine 1000 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Initial oral dose of 750 mg
Number of subjects: 10
Study: 7063342

Group type: EXPERIMENTAL
Intervention: Criterion target only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varied targets (not criterion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single target (not criterion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (rested)
Number of subjects: 0
Study: 31914147

Group type: EXPERIMENTAL
Intervention: iLookOut online education program
Number of subjects: 11065
Study: 31377284

Group type: EXPERIMENTAL
Intervention: Teprotumumab (fully human monoclonal IGF‐1R antagonist antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30382734

Group type: EXPERIMENTAL
Intervention: Juvenile Justice Anger Management (JJAM) Treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 70
Study: 27457560

Group type: EXPERIMENTAL
Intervention: YH0618 soup 6 days a week for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list (Control)
Number of subjects: 0
Study: 25004917

Group type: EXPERIMENTAL
Intervention: Early rehabilitation intervention (n=196)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Usual care (n=193)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 389
Study: 23114224

Group type: EXPERIMENTAL
Intervention: Electronic decision support (EDS) tool for TIA/stroke management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 20127058

Group type: EXPERIMENTAL
Intervention: 0.2 microg/kg body weight remifentanil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.4 microg/kg body weight remifentanil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.6 microg/kg body weight remifentanil
Number of subjects: 60
Study: 17040483

Group type: EXPERIMENTAL
Intervention: Immediate periodontal therapy (early treatment)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Usual care followed by periodontal therapy (deferred treatment)
Number of subjects: 193
Study: 16232154

Group type: EXPERIMENTAL
Intervention: MIG-99 (6.25 mg t.i.d.)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: MIG-99
Number of subjects: 170
Study: 11937616

Group type: EXPERIMENTAL
Intervention: Initial gun acquisitions
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Most recent gun acquisitions
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gun acquisition sources
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gun acquisition methods
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Community involvement in gun acquisition
Number of subjects: 45
Study: 10195680

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 53
Study: 7780891

Group type: EXPERIMENTAL
Intervention: Ofloxacin drops (0.3% solution, 10 drops)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Tobramycin drops (0.3% solution, 10 drops) with erythromycin ointment post-surgery
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 49
Study: 1412681

Group type: EXPERIMENTAL
Intervention: Autologous blood drainage and transfusion device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard suction drainage
Number of subjects: 0
Study: 4014191

Group type: EXPERIMENTAL
Intervention: antismoking intervention
Number of subjects: 935
Study: 30924310

Group type: EXPERIMENTAL
Intervention: HAM-RS2 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29775805

Group type: EXPERIMENTAL
Intervention: New subsolid nodules detected after baseline screening
Number of subjects: 7557

Group type: EXPERIMENTAL
Intervention: New subsolid nodules
Number of subjects: 7557

Group type: EXPERIMENTAL
Intervention: Subsolid nodules with additional follow‐up screening
Number of subjects: 7557
Study: 27356102

Group type: EXPERIMENTAL
Intervention: High-protein diet (25%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal-protein diet (15%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-protein diet (5%)
Number of subjects: 24
Study: 26633481

Group type: EXPERIMENTAL
Intervention: CDRI 08 (special extract of Bacopa monnieri)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24204790

Group type: EXPERIMENTAL
Intervention: 3% hypohydration (3H)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 4% hypohydration (4H)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Euhydrated (EU)
Number of subjects: 32
Study: 21504616

Group type: EXPERIMENTAL
Intervention: Fluconazole in situ gels (0.5% w/v) for 14 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fluconazole tablets (100 mg/day) for 14 days
Number of subjects: 45
Study: 18291275

Group type: EXPERIMENTAL
Intervention: Intraosseous injection using the IntraFlow system
Number of subjects: 30

Group type: COMPARATOR
Intervention: IA nerve block
Number of subjects: 30
Study: 16908767

Group type: EXPERIMENTAL
Intervention: Skeletonized ITA
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonskeletonized ITA
Number of subjects: 48
Study: 12697850

Group type: EXPERIMENTAL
Intervention: Decision Board plus medical consultation
Number of subjects: 176

Group type: COMPARATOR
Intervention: Medical consultation alone
Number of subjects: 176
Study: 10634373

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9021813

Group type: EXPERIMENTAL
Intervention: Propacetamol (30 mg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Propacetamol (15 mg/kg)
Number of subjects: 34
Study: 8199795

Group type: EXPERIMENTAL
Intervention: Amitriptyline prescribed by a psychiatrist
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy from a clinical psychologist
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Counselling and case work by a social worker
Number of subjects: 121

Group type: COMPARATOR
Intervention: Routine care by a general practitioner
Number of subjects: 121
Study: 3071176

Group type: EXPERIMENTAL
Intervention: Buprenorphine (Temgesic)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 76
Study: 29379114

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) plus a weekly goal-setting group
Number of subjects: 77

Group type: COMPARATOR
Intervention: Portable cognitive-games (CG)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both VR + CG and VR + CR
Number of subjects: 77
Study: 27115772

Group type: EXPERIMENTAL
Intervention: Thai Traditional Herbal Formula (TTHF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mebendazole
Number of subjects: 15
Study: 24395315

Group type: EXPERIMENTAL
Intervention: Physiotherapy (group 1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Acromioplasty and physiotherapy (group 2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rotator cuff repair, acromioplasty and physiotherapy (group 3)
Number of subjects: 180
Study: 22939029

Group type: EXPERIMENTAL
Intervention: Compensatory cognitive training + standard pharmacotherapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard pharmacotherapy alone
Number of subjects: 69
Study: 19165785

Group type: EXPERIMENTAL
Intervention: HA/Coll/mTGase 0/100
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: HA/Coll/mTGase 80/20
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: mTGase-crosslinked samples
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Scaffolds with mTGase treatment
Number of subjects: 2
Study: 18434733

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2159
Study: 15955154

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate or budesonide, initial dose of 300, 400 or 600 microg/day, reduced to maintenance level of 200, 300 or 400 microg/day after stabilization.
Number of subjects: 86
Study: 11992983

Group type: EXPERIMENTAL
Intervention: Physical training for eight weeks at 50% of baseline VO2max
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Relaxation therapy for eight weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 8109759

Group type: EXPERIMENTAL
Intervention: mivacurium 0.2 mg/kg, IV (Group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: succinylcholine 1 mg/kg, IV (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mivacurium 0.2 mg/kg, IV (Group III)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: neostigmine 2.5 mg and glycopyrrolate 0.5 mg, IV (Group III)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mivacurium (all groups)
Number of subjects: 60

Group type: COMPARATOR
Intervention: succinylcholine (Group I)
Number of subjects: 60
Study: 2660974

Group type: EXPERIMENTAL
Intervention: Transrectal needle aspiration biopsy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Core biopsy
Number of subjects: 88
Study: 30955365

Group type: EXPERIMENTAL
Intervention: High dietary intake of folate
Number of subjects: 3185

Group type: EXPERIMENTAL
Intervention: High dietary intake of vitamin B6
Number of subjects: 3185

Group type: COMPARATOR
Intervention: B vitamins (thiamin, niacin, riboflavin)
Number of subjects: 3185
Study: 27513733

Group type: EXPERIMENTAL
Intervention: Isometric leg extension holds at 60 degrees knee flexion (80% of their maximal voluntary isometric contraction)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic leg extension (at 80% of their 8 repetition maximum)
Number of subjects: 20
Study: 25145943

Group type: EXPERIMENTAL
Intervention: Veterans
Number of subjects: 6577

Group type: COMPARATOR
Intervention: Non-veterans
Number of subjects: 6577

Group type: EXPERIMENTAL
Intervention: Vietnam War veterans
Number of subjects: 6577
Study: 23550856

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 mg, repeated after 4 h as needed
Number of subjects: 130

Group type: COMPARATOR
Intervention: Misoprostol 25 μg, repeated after 4 h as needed
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 130
Study: 21334136

Group type: EXPERIMENTAL
Intervention: PSA <3.0 ng/ml screening
Number of subjects: 15758

Group type: EXPERIMENTAL
Intervention: Interval cancers detected
Number of subjects: 15758

Group type: EXPERIMENTAL
Intervention: Screen-detected cancers
Number of subjects: 15758

Group type: EXPERIMENTAL
Intervention: Overall PCa mortality
Number of subjects: 15758
Study: 20048486

Group type: EXPERIMENTAL
Intervention: Lean fish diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beef diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cholesterol-free diet
Number of subjects: 0
Study: 17313607

Group type: EXPERIMENTAL
Intervention: Graphologists
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Internists
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both evaluators (Graphologists and Internists)
Number of subjects: 80
Study: 15562900

Group type: EXPERIMENTAL
Intervention: Amoxicillin (10 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cefprozil (10 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 60
Study: 11560366

Group type: EXPERIMENTAL
Intervention: 15% body mass load in a bookbag
Number of subjects: 30

Group type: COMPARATOR
Intervention: Empty pack (no load)
Number of subjects: 30
Study: 9778071

Group type: EXPERIMENTAL
Intervention: Fosinopril 5 to 20 mg every day
Number of subjects: 254

Group type: COMPARATOR
Intervention: Enalapril 5 to 20 mg every day
Number of subjects: 254
Study: 7609497

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg once daily for 1 week
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily for 1 week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 40
Study: 2672434

Group type: EXPERIMENTAL
Intervention: True plasma exchange
Number of subjects: 294

Group type: COMPARATOR
Intervention: Sham plasma exchange
Number of subjects: 294
Study: 1083792

Group type: EXPERIMENTAL
Intervention: Vestibular-proprioceptive stimulation (horizontal or semivertical position)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pacifier sucking
Number of subjects: 48

Group type: COMPARATOR
Intervention: Upright position
Number of subjects: 48
Study: 31308627

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg) and celecoxib (200 mg) 2 hrs before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29113045

Group type: EXPERIMENTAL
Intervention: Sourdough wheat bread
Number of subjects: 26

Group type: COMPARATOR
Intervention: Yeast-fermented wheat bread
Number of subjects: 26
Study: 25467705

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30